Boehringer Ingelheim Hits Milestone in CKD: Promising Phase II Results with Aldosterone Synthase Inhibitor + Empagliflozin

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...

November 06, 2023 | Monday | News
Bayer Unveils New Biomarker Study Supporting Kerendia®'s Mechanism in CKD Patients with T2D

At the American Society of Nephrology’s (ASN) Kidney Week 2023, Bayer today announced pharmacodynamic data on Kerendia® (finerenone), the first n...

November 03, 2023 | Friday | News
Revvity's CEO Prahlad Singh Navigates Stormy Q3 Waters, Pledges Stronger Future Amid Market Uncertainty

Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing oper...

October 31, 2023 | Tuesday | Company results
Merck Expands Oncology Portfolio with Hengrui Partnership, Promises More Treatment Options for Difficult-to-Treat Cancers

Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...

October 31, 2023 | Tuesday | News
AI-Powered Immune Phenotyping by Lunit SCOPE IO Marks First TKI-Resistant Lung Cancer Immunotherapy Success

Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...

October 25, 2023 | Wednesday | News
Next-Gen Cologuard Test Outperforms FIT in Cancer Detection: BLUE-C Study Results

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study r...

October 23, 2023 | Monday | News
Thermo Fisher Partners with Boehringer Ingelheim on Companion Diagnostic for NSCLC Treatment

To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targete...

October 20, 2023 | Friday | News
Charles River Labs Offers Pediatric PDX Collection for Oncology Research Access

Charles River Laboratories International, Inc. announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collec...

October 17, 2023 | Tuesday | News
Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Helps support faster diagnosis, enabling earlier treatment of eye conditions Enables a more digitally connected primary care exam Facilitates collabora...

October 17, 2023 | Tuesday | News
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...

October 16, 2023 | Monday | News
MHTC and Experts Unite to Spotlight Breast Cancer Awareness

In conjunction with breast cancer awareness month, the Malaysia Healthcare Travel Council (MHTC) together with Subang Jaya Medical Centre, organised a thou...

October 16, 2023 | Monday | News
FDA Clears Pfizer's BRAFTOVI® + MEKTOVI® for Lung Cancer with BRAF V600E Mutation

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) fo...

October 13, 2023 | Friday | News
GE Healthcare Inks $44M Deal with BARDA for AI-Enhanced Ultrasound Tech to Boost Trauma Care and Disaster Preparedness

GE HealthCare (Nasdaq: GEHC) today announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA)&mdash...

October 13, 2023 | Friday | News
Danaher Unveils a New Identity with a Singular Focus on Advancing Human Health through Science and Technology

Danaher's new motto is "Accelerating the Power of Science and Technology to Improve Human Health." The organization's renewed focus is on driving innovatio...

October 12, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close